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Identity 
Note: belongs to the group of 'small blue round cell' 
tumours of the children, and differential diagnosis w th 
primitive neurectodermal tumours (PNET), lymphoma, 
Ewing's tumour, and rhabdomyosarcoma may be 
difficult. 
Clinics and pathology 
Disease  
Tumour of the sympathetic nervous system: 
medulloadrenal gland (50%), abdominal (25%), 
thoracic (15%), cervical or pelvic paraspinal ganglia; 
metastatic at diagnosis in 60% of cases (lymph nodes, 
bones and bone marrow, liver, skin). 
Embryonic origin 
Neural crest cells. 
Etiology 
Unknown; possible excess in neurofibromatosis type I, 
Wiedemann-Beckwith syndrome, and maternal 
exposure to phenyl hydantoin; exceptional familial 
cases. 
Epidemiology 
Incidence is 5-10 per million children per yr; 10% of 
cancers in childhood; half cases by the age of 2 yrs, 
90% before 6 yrs. 
Clinics 
Presenting signs are according to the localization of the 
tumoural mass; high catecholamin excretion. 
Pathology 
Tumours may exhibit various degrees of 
differentiation: 
1- Neuroblastoma: undifferentiated cells that may be 
arranged in rosettes surrounding a fibrillar centre; 
2- Ganglioneuroblastoma: presenting with more 
fibrillar material and a mixture of the above described 
with >50% of more mature cells; 
3- Ganglioneuroma composed of well differentiated 
ganglion cells and Schwann cells; a given tumour may
contain more and less mature cell areas. 
Staging (Evans): 
Stage I: confined to the organ or structure of origin, 
Stage II: extending beyond the organ, but not crossing 
the midline (e.g. homolateral lymph nodes may be 
involved), 
Stage III: extending and crossing the midline, 
Stage IV: distant metastases, 
Stage IVs: stage I or II otherwise in children aged < 1 
yr, with metastases in: liver, skin, bone marrow, but not 
in the bones. 
Treatment 
Surgery and/or radiation therapy, and/or chemotherapy. 
Evolution 
Spontaneous (and treatment induced) regression or 
differenciation into benign cells (ganglioneuroma) 
occurs rarely in tumours (mainly in infant cases). 
Prognosis 
Prognosis is very poor in most cases (median survival 1 
yr); good outcome (90%) only for patients with lymph 
nodes negative for tumour (POG stage A); younger 
patients have better outcome than older patients; 
cytogenetic and genetic anomalies are of important 
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Genetics 
Note: heterogenous disease from the genetic viewpoint; 
90% cases exhibit genetic abnormalities. 
Cytogenetics 
Morphological cytogenetics 
Two types can be delineated according to ploidy: 
- Aneuploid tumours (near triploid, pentaploid or 
hexaploid), with whole chromosome anomalies, often 
with relative gains of chromosomes 17, 7, 6, relative 
losses of chromosomes 11, 14, X (molecular 
cytogenetics: detection with comparative genomic 
hybridization (CGH)); these are low grade tumours, 
with good prognosis. 
- Diploid and/or tetraploid tumours, with del(1p) -
minimal critical region being 1p36- in 40% cases, 
del(11q), partial trisomy for 17q21-qter (in 90% of high 
grade tumours), DM or HSR (N-myc amplification); 
these anomalies are often associated, found in high
grade tumours, and bear a grave prognosis. 




Nuclear protein; contains a helix-loop-helix and a 
leucine zipper; transcription factor. 




Amplification of NMYC is found in various tumours, 
in particular neuroblastoma; the level of amplificat on 








To be noted 
Screening programs in several countries could not 
induce a fall in mortality 
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